Giannatempo P, Cerbone L, Calabro F. Is This the End of the Cisplatin Eligibility Era in Muscle-invasive Bladder Cancer? Letter in reference to: Matthew D. Galsky, Begona P. Valderrama, Marco Maruzzo, et al. Enfortumab vedotin and pembrolizumab in cisplatin-eligible bladder cancer. N Eng Eur Urol 2026 Sep 18:S0302-2838(26)02368-7. doi: 10.1016/j.eururo.2026.
PMID: 42760245